bèta
Trial Radar AI
De klinische studie NCT05414396 voor Diabetes mellitus, Obesitas-gerelateerde kwaadaardige neoplasma is actief, niet rekruterend. Bekijk de kaartweergave van de Klinische Studies Radar en de AI-ontdekkingstools voor alle details. Of stel hier een vraag.
Eén studie komt overeen met de filtercriteria
Kaartweergave
Terug naar zoekresultaten

Eat, Move, Live Program for the Reduction of Cancer and Chronic Disease Risk in Underserved Communities

Actief, niet rekruterend
Informatie over klinische studies is voornamelijk in het Engels beschikbaar. Trial Radar AI kan echter helpen! Klik op 'Leg studie uit' om de informatie over de studie te bekijken en te bespreken in de taal van uw keuze.
De klinische studie NCT05414396 is een interventioneel studie bij Diabetes mellitus, Obesitas-gerelateerde kwaadaardige neoplasma met de status actief, niet rekruterend. Het doel is om 347 deelnemers te includeren vanaf 20 maart 2018. De studie wordt geleid door City of Hope Medisch Centrum en de voltooiing is gepland op 12 oktober 2026. Laatste update op ClinicalTrials.gov: 5 december 2025.
Beknopte samenvatting
This clinical trial tests the Eat, Move, Live (EML) Program in reducing the risk of chronic diseases among underserved communities by improving healthy lifestyle practices, increasing physical activity and encouraging healthy eating behaviors. EML is a series of free culturally and linguistically appropriate nutrition and physical activity sessions. The interactive education segment of the EML Program is culturally responsive, and based on the community EML program, and topics will include: nutrition guidelines, reading food labels, recipe modification and healthy food preparation, eating healthy on a budget, chronic diseases information and prevention strategies. The EML program may help reduce the risk of cancer and chronic diseases by encouraging more physical activity and healthy eating behaviors.
Uitgebreide beschrijving
PRIMARY OBJECTIVES:

I. To evaluate program by assessing in combination with standard of care metformin: Changes in participants' knowledge, attitudes, and behavior.

II. To evaluate program by assessing in combination with standard of care metformin: Changes in body measurements.

III. To evaluate program by assessing in combination with standard of care metformin: Changes in biomarkers.

OUTLINE:

Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.

Officiële titel

Reducing Cancer and Chronic Disease Risk in Underserved Communities: Eat, Move, Live Program

Aandoeningen
Diabetes mellitusObesitas-gerelateerde kwaadaardige neoplasma
Andere studie-ID's
NCT-ID
NCT05414396
Startdatum (Werkelijk)
2018-03-20
Laatste update geplaatst
2025-12-05
Verwachte einddatum
2026-10-12
Inschrijving (Geschat)
347
Studietype
Interventioneel
FASE
N.v.t.
Status
Actief, niet rekruterend
Primaire doel
Ondersteunende zorg
Toewijzing
N.v.t.
Interventiemodel
Enkele groep
Blindering
Geen (Open-label)
Armen / Interventies
Deelnemersgroep/StudiearmInterventie/Behandeling
ExperimenteelSupportive care (EML program)
Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.
Gedragsinterventie
Attend EML program sessions
Vragenlijstadministratie
Ancillary studies
Primaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Changes in attitudes and beliefs as measured by questionnaires from baseline to week 12
Attitudes and beliefs regarding causes of diabetes asked in questionnaire, measured by endorsing one of the Likert-type scale values ranging from 1 (Agree) to 7 (Disagree).
Baseline and week 12
Changes in behavior as measured by questionnaires from baseline to week 12
Behaviors related to food consumption asked in questionnaires, measured by endorsing one of "None", "1", "2-3", "4-6", "7 or more".
Baseline and week 12
Changes in height from baseline to week 12
Height measured in meters
Baseline to 12 weeks
Changes in weight from baseline to week 12
Weight measured in Kilograms
Baseline to 12 weeks
Changes in waist circumference from baseline to week 12
Hip circumference measured in centimeters
Baseline to 12 weeks
Changes in chest circumference from baseline to week 12
Chest circumference measured in centimeters
Baseline to 12 weeks
Changes in right upper arm circumference from baseline to week 12
Right upper arm circumference measured in centimeters
Baseline to 12 weeks
Changes in left upper arm circumference from baseline to week 12
Left upper arm circumference measured in centimeters
Baseline to 12 weeks
Changes in right upper thigh circumference from baseline to week 12
Right upper thigh circumference measured in centimeters
Baseline to 12 weeks
Changes in left upper thigh circumference from baseline to week 12
Left upper thigh circumference measured in centimeters
Baseline to 12 weeks
Changes in body fat percentage from baseline to week 12
Body fat percentage measured in percent using a handheld BMI machine that calculates body fat percentage.
Baseline to 12 weeks
Changes in systolic blood pressure from baseline to week 12
Systolic blood pressure measured in mmHG
Baseline to 12 weeks
Changes in diastolic blood pressure from baseline to week 12
Diastolic blood pressure measured in mmHG
Baseline to 12 weeks
Changes in hip circumference from baseline to week 12
Hip circumference measured in centimeters
Baseline to 12 weeks
Changes in biomarkers
Will be collected at baseline and follow up based on glycosylated hemoglobin (A1C) measuring guidelines.
Baseline to 12 weeks
Geschiktheidscriteria

Leeftijd van deelnemers
Volwassene, Oudere volwassene
Minimumleeftijd
18 Years
Geslachten die in aanmerking komen voor de studie
Allen
Accepteert gezonde vrijwilligers
Ja
  • Agrees to group consent at week 1
  • Age over 18
  • Able to speak and understand English and/or Spanish

  • Don't agree to group consent at week 1
  • Age younger than 18
  • Not able to speak and understand English and/or Spanish
  • Can't participate in physical activity
City of Hope Medical Center logoCity of Hope Medisch Centrum344 actieve klinische studies om te verkennen
Geen contactgegevens beschikbaar
1 Studielocaties in 1 landen

California

City of Hope Medical Center, Duarte, California, 91010, United States